Nexstim Plc · OMXHEX:NXTMH
Nexstim — H1 2023 Earnings Presentation
10 slides from Nexstim's earnings presentation, Aug 18, 2023
Slide 1: Nexstim - Personalized Brain Diagnostics and Therapy
Nexstim - Personalized Brain Diagnostics and Therapy Mikko Karvinen| CEO| Nexstim Plc Joonas Juokslahti| CFO| Nexstim Plc H1 2023Financial Results Webinar, 18 Aug 2023
Slide 2: Nexstim Story
Nexstim Story Nexstim is a Finnish, globally operating growth-oriented medical technology company. MISSION VISION VALUES • We enable personalized and • With our technological know-how • Science and clinical evidence effective therapies and and superior services, • Financial success diagnostics for c
Slide 3: Megatrends that Support our Growth
Megatrends that Support our Growth Nexstim’s unique proprietary neuronavigated TMS-technology for both diagnostic and therapy applications. 1 2 3 Technological Healthcare cost Aging population development in pressures healthcare • Population aging and a • Technological • The need for more significan
Slide 4: Our Business and Products
Our Business and Products Commercial Business System Application Europe United States Status NBS Diagnostics (Navigated Over 220 Pre-surgical FDA CE marked Business Brain systems sold mapping approved Stimulation) FDA approved NBT® Over 70 Depression CE marked with existing Therapy (Navigated system
Slide 5: Business and Financial Summary H1 2023
Nexstim Business and Financial Summary H1 2023 • During the first half of 2023, we have especially focused on • Diagnostics Business (NBS) net sales were EUR 1.3M (2022 H1: projects that are crucial for the company's strategic EUR 2.1M) with a decrease of 36.0 % competitive advantage • Therapy Busin
Slide 6: H1 2023 Key Financials
H1 2023 Key Financials EUR in thousands 1–6/2023 1–6/2022 Change-% 1–12/2022 Net Sales 2.5M€ -63% 6 months 6 months 12 months • Comparable 2.5M€ -23% • Backlog Dec 31 0.0M€ (1.0M€) Net Sales 2,503.7 6,793.0 -63,1 9,526.7 Gross margin 1,992.7 6,140.2 -67,5 8,285.9 Focus on cost efficiency • Personnel
Slide 7: Key Strategic Objectives 2023
Nexstim Key Strategic Objectives 2023 1 2 3 Profitable comparable net The launch of the new Expanding the network of sales growth, leading to a NBS 6 product, enabling Nexstim exclusive positive EBITDA easy-to-use systems and collaboration clinics (operating result before the use of future primarily
Slide 8: NBS 6 – future of the Nexstim system
NBS 6 – future of the Nexstim system Developing and lauching a new product generation is an essential part of Nexstim’s work during the 2020-2024 strategy period • The NBS 6 is a new combined system that has been built 1 on Nexstim’s unique, clinically established technology. • The modular product d
Slide 9: Thank you!
Thank you! @NexstimOyj Follow us on social media: @Nexstim @NexstimTMS Nexstim Oyj Nexstim Plc Public Presentation 9
Slide 10: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj other than the date of this presentation. Nothing contained herein is, or should be relied upon (“Nexstim” or the “Company”). In connection with any presentation or review of this document, as